These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 31899993)

  • 61. A molecular signature of well-differentiated oral squamous cell carcinoma reveals a resistance mechanism to metronomic chemotherapy and novel therapeutic candidates.
    Kina S; Kawabata-Iwakawa R; Miyamoto S; Arasaki A; Sunakawa H; Kinjo T
    J Drug Target; 2021 Dec; 29(10):1118-1127. PubMed ID: 33979258
    [TBL] [Abstract][Full Text] [Related]  

  • 62. An update: emerging drugs to treat squamous cell carcinomas of the head and neck.
    Lee YS; Johnson DE; Grandis JR
    Expert Opin Emerg Drugs; 2018 Dec; 23(4):283-299. PubMed ID: 30376740
    [No Abstract]   [Full Text] [Related]  

  • 63. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.
    Kao HF; Lou PJ
    Head Neck; 2019 Oct; 41 Suppl 1():4-18. PubMed ID: 31573752
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Safety of drug treatments for head and neck cancer.
    Galot R; Machiels JP
    Expert Opin Drug Saf; 2016 Nov; 15(11):1527-1539. PubMed ID: 27561463
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.
    Bhatia A; Burtness B
    Drugs; 2023 Feb; 83(3):217-248. PubMed ID: 36645621
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Sacco AG; Cohen EE
    J Clin Oncol; 2015 Oct; 33(29):3305-13. PubMed ID: 26351341
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pembrolizumab Monotherapy
    Matsuo M; Masuda M; Yamauchi M; Taura M; Hashimoto K; Kogo R; Jiromaru R; Hongo T; Manako T; Nakagawa T
    In Vivo; 2023; 37(5):2188-2196. PubMed ID: 37652513
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis.
    Lau A; Yang WF; Li KY; Su YX
    Crit Rev Oncol Hematol; 2020 Sep; 153():102984. PubMed ID: 32569853
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Chemotherapy for recurrent/metastatic head and neck cancers.
    Karabajakian A; Toussaint P; Neidhardt EM; Paulus V; Saintigny P; Fayette J
    Anticancer Drugs; 2017 Apr; 28(4):357-361. PubMed ID: 28166090
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck.
    Baselga J; Trigo JM; Bourhis J; Tortochaux J; Cortés-Funes H; Hitt R; Gascón P; Amellal N; Harstrick A; Eckardt A
    J Clin Oncol; 2005 Aug; 23(24):5568-77. PubMed ID: 16009950
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen.
    Soulières D; Aguilar JL; Chen E; Misiukiewicz K; Ernst S; Lee HJ; Bryant K; He S; Obasaju CK; Chang SC; Chin S; Adkins D
    BMC Cancer; 2016 Jan; 16():19. PubMed ID: 26768732
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Łasińska I; Kolenda T; Teresiak A; Lamperska KM; Galus Ł; Mackiewicz J
    Anticancer Agents Med Chem; 2019; 19(3):290-303. PubMed ID: 30198439
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and safety of weekly paclitaxel combined with cetuximab in the treatment of pretreated recurrent/metastatic head and neck cancer patients.
    Jiménez B; Trigo JM; Pajares BI; Sáez MI; Quero C; Navarro V; Llácer C; Medina L; Rueda A; Alba E
    Oral Oncol; 2013 Feb; 49(2):182-5. PubMed ID: 23026069
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
    Sola AM; Johnson DE; Grandis JR
    Expert Opin Investig Drugs; 2019 Apr; 28(4):351-363. PubMed ID: 30753792
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).
    Klinghammer K; Gauler T; Dietz A; Grünwald V; Stöhlmacher J; Knipping S; Schroeder M; Guntinas-Lichius O; Frickhofen N; Lindeman HW; Fietkau R; Haxel B; Große-Thie C; Maschmeyer G; Zipfel M; Martus P; Knoedler M; Keilholz U
    Eur J Cancer; 2019 Nov; 122():53-60. PubMed ID: 31618704
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries.
    Lafuma A; Cotté FE; Le Tourneau C; Emery C; Gaudin AF; Torreton E; Gourmelen J; Bonastre J
    J Med Econ; 2019 Jul; 22(7):698-705. PubMed ID: 30895832
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.